Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab effect on taxane-induced endothelial progenitor cell release
NL-OMON31128Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of bevacizumab, paclitaxel and docetaxel in Nonhematologic neoplasms and breast cancer (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Effect of taxane therapy on endothelial progenitor cell release and Effect of bevacizumab on taxane-induced endothelial progenitor cell release. Planned start Sep 2007; status: not yet recruiting.
02
Drugs
bevacizumabpaclitaxeldocetaxel
03
Conditions
Nonhematologic neoplasmsbreast cancer
Beyond the preview
Go deeper on NL-OMON31128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31128.